Enhancements    

DIRECT TARGETING OF THE FKBP52 COCHAPERONE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

DIRECT TARGETING OF THE FKBP52 COCHAPERONE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
PI: Marc Cox
Sponsor: CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM
Biological Sciences
Amount awarded: $502,819

Dr. Cox’s novel prostate cancer drugs developed during this project are anticipated to offer positive properties of anti-androgen drugs while preventing undesirable side effects. The unique mechanism of action of these drugs will lead to more potent and effective drugs for the treatment of castration-resistant prostate cancer, thereby filling a major unmet need in prostate cancer therapy.

Posting date: Thu, 02/23/2017

Award start date: Sat, 07/01/2017
Award end date: Tue, 06/30/2020